175 related articles for article (PubMed ID: 19199650)
1. Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening.
Peach ML; Tan N; Choyke SJ; Giubellino A; Athauda G; Burke TR; Nicklaus MC; Bottaro DP
J Med Chem; 2009 Feb; 52(4):943-51. PubMed ID: 19199650
[TBL] [Abstract][Full Text] [Related]
2. Developing Antagonists for the Met-HGF/SF Protein-Protein Interaction Using a Fragment-Based Approach.
Winter A; Sigurdardottir AG; DiCara D; Valenti G; Blundell TL; Gherardi E
Mol Cancer Ther; 2016 Jan; 15(1):3-14. PubMed ID: 26712116
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
Parikh PK; Ghate MD
Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
[TBL] [Abstract][Full Text] [Related]
4. Genetic targeting of the kinase activity of the Met receptor in cancer cells.
Arena S; Pisacane A; Mazzone M; Comoglio PM; Bardelli A
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11412-7. PubMed ID: 17595299
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
[TBL] [Abstract][Full Text] [Related]
6. Targeting the HGF/Met signalling pathway in cancer.
Cecchi F; Rabe DC; Bottaro DP
Eur J Cancer; 2010 May; 46(7):1260-70. PubMed ID: 20303741
[TBL] [Abstract][Full Text] [Related]
7. Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities.
Kim KS; Zhang L; Schmidt R; Cai ZW; Wei D; Williams DK; Lombardo LJ; Trainor GL; Xie D; Zhang Y; An Y; Sack JS; Tokarski JS; Darienzo C; Kamath A; Marathe P; Zhang Y; Lippy J; Jeyaseelan R; Wautlet B; Henley B; Gullo-Brown J; Manne V; Hunt JT; Fargnoli J; Borzilleri RM
J Med Chem; 2008 Sep; 51(17):5330-41. PubMed ID: 18690676
[TBL] [Abstract][Full Text] [Related]
8. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
Tiedt R; Degenkolbe E; Furet P; Appleton BA; Wagner S; Schoepfer J; Buck E; Ruddy DA; Monahan JE; Jones MD; Blank J; Haasen D; Drueckes P; Wartmann M; McCarthy C; Sellers WR; Hofmann F
Cancer Res; 2011 Aug; 71(15):5255-64. PubMed ID: 21697284
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T
Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
[TBL] [Abstract][Full Text] [Related]
10. Identification of Phytochemicals Targeting c-Met Kinase Domain using Consensus Docking and Molecular Dynamics Simulation Studies.
Aliebrahimi S; Montasser Kouhsari S; Ostad SN; Arab SS; Karami L
Cell Biochem Biophys; 2018 Jun; 76(1-2):135-145. PubMed ID: 28852971
[TBL] [Abstract][Full Text] [Related]
11. Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors.
Yuan H; Liu Q; Zhang L; Hu S; Chen T; Li H; Chen Y; Xu Y; Lu T
Eur J Med Chem; 2018 Jan; 143():491-502. PubMed ID: 29202410
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
Cui JJ; McTigue M; Nambu M; Tran-Dubé M; Pairish M; Shen H; Jia L; Cheng H; Hoffman J; Le P; Jalaie M; Goetz GH; Ryan K; Grodsky N; Deng YL; Parker M; Timofeevski S; Murray BW; Yamazaki S; Aguirre S; Li Q; Zou H; Christensen J
J Med Chem; 2012 Sep; 55(18):8091-109. PubMed ID: 22924734
[TBL] [Abstract][Full Text] [Related]
13. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents.
Chuang CH; Cheng TC; Leu YL; Chuang KH; Tzou SC; Chen CS
Int J Mol Sci; 2015 Feb; 16(2):3202-12. PubMed ID: 25648320
[TBL] [Abstract][Full Text] [Related]
15. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
16. Tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells: kinetic and molecular docking studies.
Larsen CA; Bisson WH; Dashwood RH
J Med Chem; 2009 Nov; 52(21):6543-5. PubMed ID: 19839593
[TBL] [Abstract][Full Text] [Related]
17. Identification of Flavonoids as Putative ROS-1 Kinase Inhibitors Using Pharmacophore Modeling for NSCLC Therapeutics.
Parate S; Kumar V; Hong JC; Lee KW
Molecules; 2021 Apr; 26(8):. PubMed ID: 33917039
[TBL] [Abstract][Full Text] [Related]
18. Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates.
Underiner TL; Herbertz T; Miknyoczki SJ
Anticancer Agents Med Chem; 2010 Jan; 10(1):7-27. PubMed ID: 20015007
[TBL] [Abstract][Full Text] [Related]
19. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
Nan X; Li HJ; Fang SB; Li QY; Wu YC
Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
[TBL] [Abstract][Full Text] [Related]
20. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
